Novel trial designs for high-risk myelodysplastic syndromes

Lancet Oncol. 2016 Apr;17(4):410-412. doi: 10.1016/S1470-2045(16)00073-5. Epub 2016 Mar 9.

Authors

Emilio P Alessandrino¹, Matteo G Della Porta²

Affiliations

¹ Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo & University of Pavia Medical School, 27100 Pavia, Italy. Electronic address: alessandrino@smatteo.pv.it.
² Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo & University of Pavia Medical School, 27100 Pavia, Italy.

PMID: 26968356
DOI: 10.1016/S1470-2045(16)00073-5

No abstract available

Publication types

Comment

MeSH terms

Humans
Myelodysplastic Syndromes*
Prognosis